RESET-Systemic Lupus Erythematosus (SLE)
- Study IRB#:2000036467
- Last Updated:04/30/2026
RESET-SLE™ is a phase 1/2 clinical trial being conducted to evaluate the effects of the investigational cell treatment CABA-201 for the treatment of SLE in patients with active LN or active SLE without renal involvement.
Contact Us
For more information about this study, including how to volunteer, contact:
Yale Lupus Research Program
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
RESET-SLE™ is a phase 1/2 clinical trial being conducted to evaluate the effects of the investigational cell treatment CABA-201 for the treatment of SLE in patients with active LN or active SLE without renal involvement.
Eligibility Criteria
- Are 18 to 65 years of age
- Have a diagnosis of SLE
- Have a positive antinuclear antibody (ANA) titer or antidsDNA antibody
- For LN participants only: Have active, biopsy-proven LN class III or IV, with or without the presence of class V
- Have active disease despite being on medications to treat lupus
- Additional requirements will apply, and only a study doctor can determine eligibility to participate in the study
Compensation for study enrollment and travel will be provided.
For more study information, visit ClinicalTrials.gov.
